Dociparstat (DSTAT) is a heparin derivative with significantly decreased anticoagulant activity; this enables dosing at higher concentrations to achieve anti-inflammatory effects that cannot be safely achieved with fully anticoagulant heparins

DSTAT’s mechanism of action is multimodal—by inhibiting several key proteins (HMGB1, Platelet Factor 4, P-selectin) involved in the hyperinflammation and coagulopathy that contribute to high morbidity and mortality in severe COVID-19 DSTAT is uniquely positioned as a candidate treatment to address these important aspects of COVID-19 pathophysiology

This study aims to generate meaningful data to potentially advance the treatment of severe COVID-19 through scientific rigor and the use of a double-blind, randomized, placebo-controlled study design